Call Extraction: Kendall & Meaghan — License Onboarding & Strategic Planning

DDX ID: 0185 Date: 2025-12-19 Duration: ~25 minutes Participants: Kendall Thiessen (CDL, contracts/regulatory), Meaghan DePeter (MedScout CSM). Call type: First-week platform onboarding. Kendall exploring capabilities for regulatory and business development use cases. Triage: Rich. Kendall’s CON strategies are articulated more concretely than in 0076 — specific tactics with names (“Beat Your Neighbor”), specific methodologies (drive-time analysis, patient journey economics), and specific market expansion context.

Distinct Insights

1. “Beat Your Neighbor” — state rivalry as a CON strategy

What: Kendall: “Rhode Island, Connecticut’s beating you and it turns out that works. They really hate each other… I touched the nerve.” He discovered this accidentally — misspoke in a meeting and got a strong defensive reaction. Now their entire Rhode Island strategy centers on per-capita PET comparisons showing Rhode Island trailing Connecticut and Massachusetts.

So what: CDL’s regulatory arguments aren’t just about data tables and utilization projections — they exploit regional psychology. Per-capita PET utilization comparisons are dry statistics nationally, but framing them as “your neighbor is doing better” creates emotional urgency with state decision-makers. This works because CON hearings aren’t purely rational — they involve state officials who care about healthcare delivery rankings. The strategy may be repeatable in states with strong regional identities — Kendall proved it works in New England. Whether per-capita comparisons create the same emotional urgency in, say, Midwestern CON states (Illinois, Michigan, Ohio) is untested as of this call. The data is the same claims analysis CDL does for targeting, just repackaged as a competitive benchmark between states rather than between facilities.

Speaker credibility: Kendall, speaking from direct experience in the Rhode Island hearing. Very high — he saw the reaction. Scope: CON states broadly. Most effective in regions with strong state identities (New England, Midwest). Motion: Regulatory.

2. Two distinct regulatory audiences with different data needs

What: Kendall identified two different approval processes CDL faces:

• State DOH (Department of Health) CON process: “Very rigorous. They look at, they want exact tables, they want figures.”
• Local planning board approvals: “They’re the ones who worry about, oh, we don’t want a trailer on our parking lot… it’s more of the planning boards, not in my backyard.”

For DOH: detailed utilization data, demand projections, capacity analysis. For planning boards: community impact, drive-time analysis showing access gaps, “why does this community need this technology?”

So what: CDL doesn’t face one regulatory process — they face two, with different audiences, different data needs, and different persuasion strategies. State DOH hearings require quantitative rigor (Kendall’s math background serves him here). Planning board approvals require community narrative (why residents need this, how far they currently travel). The same underlying claims data supports both, but the presentation differs completely. A DOH hearing gets utilization tables and capacity calculations. A planning board gets a drive-time map showing a 35-40 minute gap in access and a story about patients who can’t get tested close to home. This dual-audience reality explains why Kendall needs both analytical tools (claims data, capacity modeling) and geographic tools (drive-time mapping).

Speaker credibility: Kendall, across ~20 applications in multiple states. Very high. Scope: All CON states (DOH process) plus primarily Western states (planning boards, especially California where “everyone’s trying to do the mobile unit solution”). Motion: Regulatory.

3. CDL’s market expansion is entering harder territory

What: Kendall: “Now that CDL has kind of expanded into the, I want to call them the easy bucket. We kind of got the early adopters and all those folks have been vetted. Now we’re getting down to that second tier of like you’re really having to fight a little bit more.” Expanding beyond TX, VA, FL into IL, MI, OH.

So what: CDL’s growth trajectory has a regulatory complexity gradient. The first wave of states (Texas, Virginia, Florida) were what Kendall calls the “easy bucket” — either no CON requirements or less competitive regulatory environments. (Texas and Florida are confirmed no-CON from the 5/5 session; Virginia’s specific status isn’t stated but Kendall groups it with the easier markets.) The second wave includes states with active CON laws that require data-driven need demonstrations before any sale can happen. This means CDL’s sales cycle in these states is structurally longer and more expensive because the regulatory phase (prove the need exists) must be won before the sales phase (convince the practice to buy from CDL) can begin. The “easy bucket” being exhausted also means CDL’s growth rate depends on their ability to win CON approvals efficiently — Kendall’s workflow bottleneck (multi-step relay through Phil) directly constrains market expansion.

Speaker credibility: Kendall, describing CDL’s expansion arc. High. Scope: Company-wide growth strategy. Motion: Regulatory + commercial strategy.

4. Patient journey economics — PET saves money by preventing unnecessary interventions

What: Kendall: “If even just one out of 100 or three out of 100 of the patients avoid an angioplasty they didn’t require, you’ve more than paid the difference on the testing cost.” Dr. Mazza published research showing PET reduces downstream interventions (angiograms, bypass surgery) compared to SPECT. Mechanism: PET’s higher diagnostic resolution enables better-optimized treatment plans, so patients get the right intervention earlier rather than undergoing procedures they don’t need.

So what: CDL has an economic argument beyond the clinical one (“PET is the preferred test”). The logic chain: PET costs more than SPECT for the initial scan (~$800 difference) → but PET’s higher diagnostic precision means fewer patients get sent for unnecessary angioplasty ($31,000) or bypass surgery → even if only 1-3 out of 100 patients avoid an unnecessary procedure, the system saves money overall → so PET isn’t a cost increase, it’s a cost reduction when measured across the full episode of care. Dr. Mazza has published data on this, but from the 2010s using his own practice patients. Kendall knows single-practice historical data won’t convince regulators — he needs population-level validation through claims-based patient journey analysis tracking 100-patient cohorts over 24-36 months. This economic argument is distinct from the clinical argument (PET is better diagnostically) and the capacity argument (existing providers are at capacity). It addresses a different concern: is PET cost-justified?

Speaker credibility: Kendall (the economic framing), Dr. Mazza (the clinical research). Mazza’s research is real but dated and single-practice. The population-level validation is still needed. Scope: Universal for CDL’s PET value proposition — applies in regulatory hearings, payer negotiations, and physician sales conversations. Motion: Regulatory + all motions (the economic argument serves everywhere).

5. Kendall’s philosophy: numbers give the framing, stories win the approval

What: Kendall: “When I can penetrate the numbers to get behind that, but I need the numbers to give the framing and then I can tell the story.” He described the human impact: “Those are eight lives out of 100 that are no longer being affected by anxiety and fear and possible chance of risk and infection.”

So what: Kendall’s approach to regulatory work synthesizes two things: quantitative evidence and human narrative. The numbers establish credibility (utilization data, capacity calculations, per-capita comparisons). The story makes it matter (a patient’s mother going through unnecessary surgery, the anxiety and recovery period, the infection risk). His math background gives him the rigor; his legal background gives him the persuasion. This has implications for how CDL packages information — claims data alone isn’t enough. The data needs to be translated into patient stories and community impact narratives to work in regulatory settings. This may also apply to CDL’s sales motion: physicians don’t buy based on claims data alone; they buy when they can connect the data to patient outcomes they care about.

Speaker credibility: Kendall, describing his own methodology. Very high. Scope: CDL’s regulatory approach, potentially applicable to sales messaging. Motion: Regulatory.

6. CDL’s clients don’t know their own data

What: Kendall: “Who are your cardiologists that are doing most of the testing? And they’re like, nah, I think it might be this Guy. I mean, they really have no idea about their data most of the time.”

So what: CDL’s clients — the practices seeking CON approval — can’t answer basic questions about their own referral patterns and volume distribution. They don’t know which physicians generate the most testing, which PCPs refer the most patients, or where their patients go for services they don’t offer. CDL ends up knowing its clients’ businesses better than the clients do, using claims data to identify volume drivers that practices can only guess at. This creates a dependency: practices need CDL not just for equipment but for the market intelligence that supports their growth and regulatory strategy. It also validates the PCP referral program Cole described in the anchor notes — practices can’t grow their referral base because they don’t even know who’s currently referring to them.

Speaker credibility: Kendall, across many client interactions. Very high — this is a pattern, not an anecdote. Scope: CDL’s client base broadly. Motion: All motions — the data gap exists across hospital and private practice clients.

7. Drive-time analysis: 35-40 minute radius for access gap mapping

What: Kendall: “Often we do what’s a drive time analysis where we even do like what’s the scope of the range 35 or 40 minutes from the office. So that we can kind of look at are there any other CT providers?”

So what: CDL uses a specific methodology for planning board approvals: map a 35-40 minute drive radius from the proposed installation site, then show what PET capacity exists within that radius. If there’s little or none, the community has an access gap — patients would need to drive further than 35-40 minutes for PET services, which is the threshold CDL uses to demonstrate need. This is more relevant for Western states and California (where planning boards care about community access) than for Eastern DOH processes (which care about utilization data). The drive-time approach also connects to patient leakage analysis: patients within the 35-40 minute radius who currently travel out of state for PET represent demand that could be served locally if the application is approved.

Speaker credibility: Kendall, standard methodology across his applications. High. Scope: Planning board approvals specifically. Less relevant for DOH CON processes. Motion: Regulatory.

Transcription Notes

• Collide AI — mentioned by Kendall as a tool he used to generate a cost savings calculator. New to term bank.
• CLM — Contract Lifecycle Management system. Kendall’s other project at CDL.
• “Easy bucket” / “second tier” — Kendall’s language for CDL’s market expansion phases. Easy = no-CON or simple-CON states. Second tier = active CON with rigorous requirements.
• Transcript confirms Kendall’s background: mathematics degree → law → IP law → healthcare law → CDL operational/regulatory role.